Year: 2022
![Paragraf raises $60 million in Series B financing Paragraf raises $60 million in Series B financing](https://www.newscienceventures.com/wp-content/uploads/2022/02/paragraf-logo_website.png)
Paragraf raises $60 million in Series B financing
Paragraf has announced the close of its $60m Series B round. The round is being led by New Science Ventures, a US deep tech investor, investing in novel scientific approaches in the Life Sciences and Information Technology sectors, which is very well aligned with Paragraf’s growth aspirations. The round included
Read More![NorthSea Therapeutics initiates Phase I trial of SEFA-6179, targeting the orphan indication intestinal failure-associated liver disease NorthSea Therapeutics initiates Phase I trial of SEFA-6179, targeting the orphan indication intestinal failure-associated liver disease](https://www.newscienceventures.com/wp-content/uploads/2020/11/Logo_NorthSea-300x111.png)
NorthSea Therapeutics initiates Phase I trial of SEFA-6179, targeting the orphan indication intestinal failure-associated liver disease
NorthSea Therapeutics B.V., (‘NST’), a biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic diseases, has announced it has initiated a Phase I study with SEFA-6179 in adult subjects, targeting the initial orphan indication of the treatment of IFALD. IFALD is a multifactorial condition
Read More